文献速递腹部CT

双层光谱探测器CT测定的细胞外容积分数:预测胰腺导管腺癌新辅助化疗疗效的潜在作用

Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
PubMed 文献 · Eur J Radiol · 2023-03-05

本研究纳入67例胰腺导管腺癌患者,在术前新辅助化疗前行动态增强双层光谱探测器CT,计算肿瘤的细胞外容积分数(ECV),并与单能CT参数比较。结果显示,化疗响应组的DECT-ECV显著低于非响应组(p=0.0104),DECT-ECV预测响应的Az值为0.798,以<26.0%为阈值时敏感度71.4%、特异度85.0%。结论提示低DECT-ECV的PDAC可能对新辅助化疗反应更好,DECT-ECV有望成为预测疗效的生物标志物。

要点

  • DECT-ECV在化疗响应组显著低于非响应组,p=0.0104。
  • DECT-ECV预测新辅助化疗响应的Az值为0.798,高于其他参数。
  • 阈值<26.0%时,敏感度71.4%、特异度85.0%、准确率83.6%。

核心结论

  • 低DECT-ECV的PDAC可能对新辅助化疗反应更好。
  • DECT-ECV有望作为预测PDAC新辅助化疗疗效的生物标志物。

研究设计与样本

  • 单中心研究,纳入67例PDAC患者,化疗前使用双层光谱探测器CT行动态增强扫描。
  • 在平扫和平衡期120-kVp等效图像上测量肿瘤和主动脉的衰减值,计算ΔHU-tumor、ΔHU-tumor/ΔHU-aorta和SECT-ECV。
  • 在平衡期测量肿瘤和主动脉的碘密度,计算肿瘤DECT-ECV,并评估其与NAC响应的相关性。
  • 以NAC疗效为参考标准,统计比较各影像参数与响应的关系。

诊断标准与关键数值

  • DECT-ECV预测NAC响应组的Az值为0.798。
  • 以DECT-ECV<26.0%为最佳截断值,预测响应组的敏感度71.4%、特异度85.0%、准确率83.6%、阳性预测值35.7%、阴性预测值96.2%。

临床应用与阅片要点

  • 对于拟行新辅助化疗的PDAC患者,可考虑测量DECT-ECV以辅助预测化疗反应。
  • DECT-ECV<26.0%提示对新辅助化疗反应较好的可能性较高。
  • DECT-ECV的阴性预测值达96.2%,低ECV患者中未响应者极少,有助于筛选可能获益人群。

局限性

  • 响应组仅7例,非响应组60例,样本量小且组间不均衡,结果需进一步验证。
  • 单中心研究,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To clarify the relationship between extracellular volume (ECV) measured by dual-energy CT (DECT) and efficacy of preoperative neoadjuvant chemotherapy (NAC) in patients with pancreatic ductal adenocarcinoma (PDAC), as compared with single-energy CT (SECT).

METHODS: We enrolled 67 patients with PDAC who underwent dynamic contrast-enhanced CT with a dual-energy CT system prior to NAC. Attenuation values were measured on unenhanced and the equilibrium-phase 120-kVp equivalent CT images for PDAC and the aorta. ΔHU-tumor, ΔHU-tumor/ΔHU-aorta, and SECT-ECV were calculated. Iodine densities of the tumor and aorta were measured in the equilibrium phase, and DECT-ECV of the tumor was calculated. Response to NAC was evaluated and the correlation between imaging parameters and response to NAC was statistically assessed.

RESULTS: Tumor DECT-ECVs were significantly lower in the response group (n = 7) than in the non-response group (n = 60), with most significant difference (p = 0.0104). DECT-ECV showed highest diagnostic value with an Az value of 0.798. When using the optimal cut off value of DECT-ECV (<26.0 %), sensitivity, specificity, accuracy, positive predictive value, and negative value for predicting response group were 71.4 %, 85.0 %, 83.6 %, 35.7 % and 96.2 %, respectively.

CONCLUSION: PDAC with lower DECT-ECV can potentially show better response to NAC. DECT-ECV might be a useful biomarker for predicting response to NAC in patients with PDAC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Fujita, Ushijima, Itoyama, et al. Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Eur J Radiol. 2023. PMID: 36907069. doi:10.1016/j.ejrad.2023.110756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。